Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade
Adoptive cell therapy (ACT), based on treatment with autologous tumor infiltrating lymphocyte (TIL)-derived or genetically modified chimeric antigen receptor (CAR) T cells, has become a potentially curative therapy for subgroups of patients with melanoma and hematological malignancies. To further im...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.578349/full |
| _version_ | 1818515508799995904 |
|---|---|
| author | Mie Linder Hübbe Ditte Elisabeth Jæhger Thomas Lars Andresen Mads Hald Andersen |
| author_facet | Mie Linder Hübbe Ditte Elisabeth Jæhger Thomas Lars Andresen Mads Hald Andersen |
| author_sort | Mie Linder Hübbe |
| collection | DOAJ |
| description | Adoptive cell therapy (ACT), based on treatment with autologous tumor infiltrating lymphocyte (TIL)-derived or genetically modified chimeric antigen receptor (CAR) T cells, has become a potentially curative therapy for subgroups of patients with melanoma and hematological malignancies. To further improve response rates, and to broaden the applicability of ACT to more types of solid malignancies, it is necessary to explore and define strategies that can be used as adjuvant treatments to ACT. Stimulation of endogenous dendritic cells (DCs) alongside ACT can be used to promote epitope spreading and thereby decrease the risk of tumor escape due to target antigen downregulation, which is a common cause of disease relapse in initially responsive ACT treated patients. Addition of checkpoint blockade to ACT and DC stimulation might further enhance response rates by counteracting an eventual inactivation of infused and endogenously primed tumor-reactive T cells. This review will outline and discuss therapeutic strategies that can be utilized to engage endogenous DCs alongside ACT and checkpoint blockade, to strengthen the anti-tumor immune response. |
| first_indexed | 2024-12-11T00:29:45Z |
| format | Article |
| id | doaj.art-8ce0c3bd309b4387a6524aeba9b2f69e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T00:29:45Z |
| publishDate | 2020-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8ce0c3bd309b4387a6524aeba9b2f69e2022-12-22T01:27:24ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-09-011110.3389/fimmu.2020.578349578349Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint BlockadeMie Linder Hübbe0Ditte Elisabeth Jæhger1Thomas Lars Andresen2Mads Hald Andersen3National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Copenhagen, DenmarkDepartment of Health Technology, Technical University of Denmark, Kongens Lyngby, DenmarkDepartment of Health Technology, Technical University of Denmark, Kongens Lyngby, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital Herlev, Copenhagen, DenmarkAdoptive cell therapy (ACT), based on treatment with autologous tumor infiltrating lymphocyte (TIL)-derived or genetically modified chimeric antigen receptor (CAR) T cells, has become a potentially curative therapy for subgroups of patients with melanoma and hematological malignancies. To further improve response rates, and to broaden the applicability of ACT to more types of solid malignancies, it is necessary to explore and define strategies that can be used as adjuvant treatments to ACT. Stimulation of endogenous dendritic cells (DCs) alongside ACT can be used to promote epitope spreading and thereby decrease the risk of tumor escape due to target antigen downregulation, which is a common cause of disease relapse in initially responsive ACT treated patients. Addition of checkpoint blockade to ACT and DC stimulation might further enhance response rates by counteracting an eventual inactivation of infused and endogenously primed tumor-reactive T cells. This review will outline and discuss therapeutic strategies that can be utilized to engage endogenous DCs alongside ACT and checkpoint blockade, to strengthen the anti-tumor immune response.https://www.frontiersin.org/article/10.3389/fimmu.2020.578349/fullcancer immunotherapyimmune checkpoint blockadecombination therapiesT-cell therapydendritic cells |
| spellingShingle | Mie Linder Hübbe Ditte Elisabeth Jæhger Thomas Lars Andresen Mads Hald Andersen Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade Frontiers in Immunology cancer immunotherapy immune checkpoint blockade combination therapies T-cell therapy dendritic cells |
| title | Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade |
| title_full | Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade |
| title_fullStr | Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade |
| title_full_unstemmed | Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade |
| title_short | Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade |
| title_sort | leveraging endogenous dendritic cells to enhance the therapeutic efficacy of adoptive t cell therapy and checkpoint blockade |
| topic | cancer immunotherapy immune checkpoint blockade combination therapies T-cell therapy dendritic cells |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2020.578349/full |
| work_keys_str_mv | AT mielinderhubbe leveragingendogenousdendriticcellstoenhancethetherapeuticefficacyofadoptivetcelltherapyandcheckpointblockade AT ditteelisabethjæhger leveragingendogenousdendriticcellstoenhancethetherapeuticefficacyofadoptivetcelltherapyandcheckpointblockade AT thomaslarsandresen leveragingendogenousdendriticcellstoenhancethetherapeuticefficacyofadoptivetcelltherapyandcheckpointblockade AT madshaldandersen leveragingendogenousdendriticcellstoenhancethetherapeuticefficacyofadoptivetcelltherapyandcheckpointblockade |